Tristel Regulatory News (TSTL)

TRISTEL plc

("Tristel" or "the Company")

Directorate Change

Tristel plc (AIM: TSTL), the manufacturer of infection control, contamination control and hygiene consumable products, announces the appointment of Christopher Samler as an Independent Non-Executive Director, with immediate effect. Christopher will be the Senior Independent Non-Executive Director.

Christopher was Chief Executive of Weston Medical Group plc, a publicly listed drug delivery development company which was bought by Aradigm in 2003. Prior to that Christopher was Chief Executive of Imutran Ltd, a biotechnology company focused on the development of genetically modified products for human transplant which he sold to Novartis. From 1988 to 1994 Christopher held various positions within Bentley Laboratories Europe b.v, finally becoming Director of the European subsidiary of Baxter International.

More recently Christopher was Non-Executive Chairman of TQ Education & Training, which was sold to Pearson plc last week and has held a number of Non-Executive positions including Ribotargets Ltd, a private biotech company developing drugs for infection and cancer sold to British Biotech plc; InterActiva GmbH, a German based bioinformatics business subsequently sold to Hybaid; and Apollo Lifts Ltd, which was sold to Schindler in May 2011. Christopher is also a founding partner of Iceni Capital a specialist private equity firm providing funding and advice to small, fast growing businesses in the service sector.

Paul Swinney, Chief Executive of Tristel, commented: "Christopher brings with him a great deal of experience in healthcare markets and we welcome his strong contribution to the Board both in terms of providing a wider strategic view of our business as well as ensuring that we maintain the best possible standards of corporate governance."

In addition Peter Clarke and Antonio Soler, both Non-Executive Directors, have signalled their intention to stand down from the Board at the forthcoming Annual General Meeting. Further details of the revised Board structure will be given to shareholders at the Annual General Meeting.

For further information:

About Tristel plc

Tristel plc is an infection prevention and contamination control business headquartered in Newmarket, United Kingdom. Its products are used to prevent hospital acquired infections, for hygiene in animal healthcare and by pharmaceutical and personal care manufacturers for contamination control. Its leading brands are Tristel (infection prevention) and Crystel (contamination control). The Group's products are considered to be amongst the highest performing biocides available to healthcare and industry. Tristel's lead technology is a proprietary chlorine dioxide formulation used to disinfect instruments and surfaces and to control legionella and biofilm build up in water.

Tristel was admitted to the London Stock Exchange AIM market in June 2005. Its stock exchange symbol is TSTL.

Additional Information

Christopher Hadley Samler, aged 54, holds no shares in the Company and other than as set out below there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Mr Samler's appointment today as a Director of the Company.

Christopher Samler is a Director / Partner or has been a Director / Partner of the following companies / partnerships during the previous five years:

Christopher was a director of Pell & Bales Ltd which went into a company voluntary arrangement in January 2011. An agreement was reached with creditors and the company continues to trade.